Harnessing Sensors to Identify Risk in Infants with the EDNA Portfolio

AngelEye’s New Sensor- Based Screening Technology Allows for Early Detection of At-Risk Neonates

AngelEye Health is pleased to add the Early Detection Neuromotor Assessments (EDNA) portfolio to its suite of solutions. EDNA is dedicated to identifying risk factors in newborns utilizing movement analysis, sensors, clinical experts, and artificial intelligence. This strategic acquisition strengthens AngelEye’s ability to harness sensors at the bedside to help care teams assess, identify, and support early intervention pathways in neonates.

Read the Press Release

Early Detection Neuromotor Assessments

With nearly 250 hospital partners and technology and almost 10,000 cameras at bedsides, the integration of EDNA’s platform into AngelEye has the unique ability to significantly impact NICU care. EDNA brings the ability to harness sensors at the bedside to help care teams assess, identify, and support early intervention pathways in neonates. 

Identifying risks, such as neuromotor, positioning, or sepsis, for example, in neonates, is challenging, which often leads to prolonged hospital stays and long-term complications. Through EDNA’s sensor-based platform, clinicians have more information to understand the neonates’ risks and can better support the baby and their family earlier in the infant’s life, leading to better outcomes. 

Read the Press Release
“Early detection is critical for improving long-term outcomes for neonates and high-risk infants. Today, without early, validated, and accessible assessments for newborns, families and clinicians wait for clinical symptoms or significant delays to be identified, which can take weeks or months. AngelEye’s acquisition of the EDNA portfolio is a game-changer, providing clinicians with essential tools to identify and stratify high-risk babies earlier.”
– Kathi Randall, NeuroNICU Consultant
 “By combining our industry-leading footprint with EDNA’s portfolio, we gain the ability to extend our reach beyond engagement and into the realm of supporting clinical care. This strategic transaction enables us to use our established relationships and infrastructure in the NICU to provide clinicians a greater capability to identify at-risk patients and support their care journey in the NICU and beyond.”
– Christopher Rand, CEO AngelEye Health
“At Nationwide Children’s Hospital, our mission is to fuel scientific discovery for better patient care and advance the field of pediatrics through collaboration and innovation. AngelEye’s acquisition of the EDNA technology aligns with this mission, holding immense potential for making early detection assessments more widely accessible, ultimately improving care for children everywhere. We’re thrilled to expand our strategic research collaboration with AngelEye Health on the EDNA portfolio within our Research Institute.”
– Matt McFarland, Nationwide Children’s Hospital Innovation Team
PROUD PARTNERS

Built on a Strong Foundation

EDNA’s algorithms and clinical service model have been developed in collaboration with leading scientists and hospitals, including Nationwide Children’s Hospital. Ongoing research is underway to validate further and discover additional sensor-based algorithms and services for newborns.

This page contains information about a medical device product that has not yet received clearance from the U.S. Food and Drug Administration (FDA). The product is currently undergoing the necessary regulatory review process, and its safety and efficacy have not yet been established. Any statements regarding the product’s potential benefits are based on preliminary data and are subject to change upon further evaluation and FDA approval.